New hope for kidney cancer: drug combo targets tumors after immunotherapy fails
NCT ID NCT07165418
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 3 trial tests whether a combination of two drugs, vorolanib and everolimus, can help people with advanced kidney cancer whose disease has worsened after immunotherapy. About 116 participants will be randomly assigned to receive either the combo or the standard drug sunitinib. The goal is to see if the combo can delay cancer growth and improve survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vorolanib tablets plus everolimus
What this could lead to
If successful, this combination could offer a new second-line treatment option for advanced kidney cancer patients who have already tried immunotherapy.
What could go wrong
This is a phase 3 trial, but it's still early to know if the combination works better than existing options. Side effects from the drugs may occur, and the study is relatively small (116 patients).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University Cancer Hospital
Beijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••